Guleria M et al. measured a similar KD (1.36 × 10–8 mol/L) for binding of [177Lu]Lu-DOTA-trastuzumab conjugated with 6 DOTA to HER2-positive SK-OV-3 human ovarian cancer cells (Guleria et al. 2021). Here, ERBB2 is linked to ovarian carcinoma.